HZNP [NASD]
Horizon Therapeutics Public Limited Company
Index- P/E20.71 EPS (ttm)3.24 Insider Own0.30% Shs Outstand230.02M Perf Week5.03%
Market Cap15.65B Forward P/E12.71 EPS next Y5.28 Insider Trans-46.70% Shs Float227.91M Perf Month12.44%
Income765.00M PEG2.20 EPS next Q1.14 Inst Own94.00% Short Float2.46% Perf Quarter-19.81%
Sales3.81B P/S4.10 EPS this Y25.30% Inst Trans0.73% Short Ratio2.01 Perf Half Y-37.62%
Book/sh21.50 P/B3.12 EPS next Y15.35% ROA8.80% Target Price105.82 Perf Year-41.10%
Cash/sh8.11 P/C8.27 EPS next 5Y9.40% ROE16.20% 52W Range57.84 - 120.54 Perf YTD-37.78%
Dividend- P/FCF11.63 EPS past 5Y33.30% ROI8.50% 52W High-44.37% Beta1.14
Dividend %- Quick Ratio3.80 Sales past 5Y26.90% Gross Margin75.40% 52W Low15.92% ATR2.20
Employees2015 Current Ratio4.00 Sales Q/Q5.30% Oper. Margin22.20% RSI (14)59.82 Volatility3.62% 3.37%
OptionableYes Debt/Eq0.52 EPS Q/Q-61.60% Profit Margin20.10% Rel Volume1.16 Prev Close66.16
ShortableYes LT Debt/Eq0.52 EarningsAug 03 BMO Payout0.00% Avg Volume2.79M Price67.05
Recom1.70 SMA205.74% SMA502.18% SMA200-23.75% Volume3,224,318 Change1.35%
Aug-04-22Downgrade SVB Leerink Outperform → Mkt Perform
Jun-14-22Initiated UBS Buy $139
Jun-06-22Resumed SVB Leerink Mkt Perform $95
May-23-22Initiated SVB Leerink Mkt Perform $95
Mar-15-22Initiated Oppenheimer Outperform $140
Dec-08-21Initiated Wells Fargo Overweight $137
Nov-19-21Upgrade Goldman Neutral → Buy $168
Oct-07-21Resumed Jefferies Buy $132
Mar-22-21Resumed Morgan Stanley Overweight $103
Mar-12-21Initiated Wolfe Research Outperform $107
Sep-09-20Initiated JP Morgan Overweight $110
Aug-27-20Initiated Citigroup Buy $112
Jan-08-20Initiated Goldman Neutral $35
Sep-26-19Initiated BofA/Merrill Buy $34
Sep-12-19Initiated Guggenheim Buy
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Oct-02-22 11:15AM
Sep-29-22 08:00AM
Sep-26-22 06:59AM
Sep-22-22 08:04AM
Sep-21-22 08:04AM
08:00AM Loading…
Sep-19-22 08:00AM
Sep-16-22 09:00AM
Sep-14-22 08:00AM
Sep-13-22 08:30AM
Sep-12-22 08:00AM
Sep-09-22 08:00AM
Sep-08-22 08:03AM
Aug-31-22 03:25PM
09:03AM
08:00AM
04:00AM Loading…
Aug-29-22 04:00AM
Aug-25-22 08:00AM
Aug-24-22 03:17PM
Aug-22-22 03:01PM
Aug-15-22 04:35PM
08:00AM
Aug-04-22 09:08AM
Aug-03-22 07:00AM
Jul-25-22 08:02AM
Jul-21-22 08:00AM
Jul-11-22 08:00AM
Jul-08-22 08:00AM
Jul-07-22 08:00AM
Jun-27-22 08:58AM
Jun-24-22 12:30PM
08:30AM Loading…
Jun-15-22 08:30AM
07:45AM
Jun-11-22 10:00AM
Jun-09-22 08:00AM
Jun-06-22 04:30PM
Jun-02-22 08:00AM
Jun-01-22 08:00AM
May-31-22 04:01PM
08:00AM
May-30-22 10:01AM
May-24-22 08:00AM
May-17-22 08:00AM
May-16-22 09:00AM
May-11-22 09:02AM
08:30AM
May-09-22 04:44PM
May-07-22 08:08AM
May-04-22 07:00AM
May-03-22 11:40AM
09:40AM
09:15AM
May-02-22 04:05PM
01:00AM
Apr-27-22 08:01AM
Apr-19-22 09:00AM
Apr-18-22 01:12PM
Apr-14-22 08:00AM
Apr-11-22 09:20AM
Mar-31-22 08:30AM
Mar-24-22 04:00AM
Mar-21-22 02:51PM
Mar-18-22 09:16AM
09:02AM
Mar-07-22 08:00AM
Mar-04-22 08:48AM
Mar-02-22 08:00AM
Mar-01-22 07:00AM
Feb-28-22 11:29AM
Feb-23-22 08:00AM
Feb-21-22 04:05PM
Feb-16-22 08:15AM
08:00AM
Feb-15-22 11:00AM
09:00AM
Feb-10-22 08:00AM
Feb-07-22 06:38PM
08:00AM
Feb-04-22 01:38PM
Feb-02-22 05:38PM
05:38PM
11:10AM
Jan-24-22 08:00AM
Jan-19-22 09:38AM
Jan-18-22 06:35AM
Jan-11-22 07:45AM
Jan-10-22 07:30AM
Jan-07-22 08:20AM
Jan-06-22 08:00AM
Dec-23-21 08:00AM
Dec-20-21 01:34PM
Dec-16-21 08:00AM
Dec-08-21 06:38PM
Dec-07-21 02:30PM
Dec-02-21 09:00AM
08:30AM
Dec-01-21 01:30AM
Nov-22-21 10:13AM
08:00AM
Nov-19-21 07:28AM
Nov-15-21 09:00AM
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clayton Sean M.EVP, General CounselAug 04Buy66.6774549,669745Aug 08 04:18 PM
Pasternak AndyEVP and Chief Business OfficerJul 29Sale82.574,850400,48334,047Jul 29 05:21 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentJul 20Sale85.005,917502,9456,969Jul 20 06:19 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentJul 19Sale85.04907,65312,886Jul 20 06:19 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentJul 07Sale85.01826,97112,976Jul 11 06:03 PM
Pasternak AndyEVP and Chief Business OfficerJun 10Sale85.3676265,04438,897Jun 13 04:19 PM
Walbert Timothy PChairman, President and CEOJun 03Option Exercise22.1425,000553,500460,826Jun 03 07:04 PM
Walbert Timothy PChairman, President and CEOJun 03Sale92.3425,0002,308,468435,826Jun 03 07:04 PM
Walbert Timothy PChairman, President and CEOMay 31Sale92.4825,0002,311,980435,549Jun 02 04:13 PM
Walbert Timothy PChairman, President and CEOMay 20Option Exercise22.1425,000553,500485,549May 20 06:15 PM
Walbert Timothy PChairman, President and CEOMay 20Sale90.0025,0002,250,000460,549May 20 06:15 PM
Walbert Timothy PChairman, President and CEOMay 11Option Exercise22.1417,600389,664478,149May 13 04:31 PM
Walbert Timothy PChairman, President and CEOMay 11Sale90.0017,6001,584,000460,549May 13 04:31 PM
Walbert Timothy PChairman, President and CEOMay 06Option Exercise22.147,400163,836467,949May 10 05:59 PM
Walbert Timothy PChairman, President and CEOMay 06Sale90.867,400672,342460,549May 10 05:59 PM
Walbert Timothy PChairman, President and CEOMay 02Sale96.0425,0002,401,006460,549May 04 04:24 PM
Walbert Timothy PChairman, President and CEOApr 22Option Exercise22.1425,000553,500510,549Apr 22 06:49 PM
Walbert Timothy PChairman, President and CEOApr 22Sale106.5925,0002,664,632485,549Apr 22 06:49 PM
Hoelscher Paul W.EVP, CFOApr 20Option Exercise22.1450,0001,107,00051,049Apr 22 06:47 PM
Hoelscher Paul W.EVP, CFOApr 20Sale114.7150,0005,735,4491,049Apr 22 06:47 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentApr 18Sale115.648,098936,45313,058Apr 20 04:13 PM
DesJardin Michael A.EVP, Technical OperationsApr 12Sale113.1220,2142,286,70382,346Apr 14 04:49 PM
Walbert Timothy PChairman, President and CEOApr 08Option Exercise22.1425,000553,500510,549Apr 08 04:11 PM
Walbert Timothy PChairman, President and CEOApr 08Sale112.3825,0002,809,521485,549Apr 08 04:11 PM
Hoelscher Paul W.EVP, CFOApr 06Option Exercise21.27215,3354,580,417216,384Apr 08 04:09 PM
Hoelscher Paul W.EVP, CFOApr 06Sale110.0191,71010,089,02666,673Apr 08 04:09 PM
Hoelscher Paul W.EVP, CFOApr 06Sale110.01215,33523,688,7881,049Apr 08 04:09 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerApr 06Sale110.0242,0094,621,87210,629Apr 08 04:07 PM
Walbert Timothy PChairman, President and CEOMar 30Sale105.2650,0005,262,787485,549Apr 01 04:10 PM
Walbert Timothy PChairman, President and CEOMar 25Option Exercise22.1425,000553,500560,549Mar 25 06:40 PM
Walbert Timothy PChairman, President and CEOMar 25Sale109.3725,0002,734,340535,549Mar 25 06:40 PM
Hoelscher Paul W.EVP, CFOMar 25Sale110.0066372,930158,383Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 24Sale110.001,481162,910159,046Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 23Option Exercise15.9626,090416,39627,139Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 23Sale110.0111,6991,287,018160,527Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 23Sale110.0026,0902,870,0021,049Mar 25 06:38 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMar 18Option Exercise22.148,531188,87652,638Mar 21 04:25 PM
Walbert Timothy PChairman, President and CEOMar 11Option Exercise22.1425,000553,500560,549Mar 11 05:17 PM
Walbert Timothy PChairman, President and CEOMar 11Sale100.9325,0002,523,314535,549Mar 11 05:17 PM
DesJardin Michael A.EVP, Technical OperationsMar 02Sale97.1935,0003,401,752102,560Mar 04 04:19 PM
Pasternak AndyEVP and Chief Business OfficerFeb 18Sale94.821,313124,49939,659Feb 18 04:42 PM
Walbert Timothy PChairman, President and CEOFeb 11Option Exercise22.1425,000553,500610,549Feb 11 04:16 PM
Walbert Timothy PChairman, President and CEOFeb 11Sale97.4125,0002,435,242585,549Feb 11 04:16 PM
Walbert Timothy PChairman, President and CEOFeb 01Option Exercise0.009,087044,690Feb 02 04:25 PM
Walbert Timothy PChairman, President and CEOJan 31Sale91.85100,0009,184,983585,549Jan 31 05:26 PM
Walbert Timothy PChairman, President and CEOJan 28Option Exercise22.1425,000553,500710,549Jan 31 05:26 PM
Walbert Timothy PChairman, President and CEOJan 28Sale90.0025,0002,250,000685,549Jan 31 05:26 PM
DesJardin Michael A.EVP, Technical OperationsJan 21Option Exercise0.003,6790139,385Jan 24 05:07 PM
Hoelscher Paul W.EVP, CFOJan 21Option Exercise0.005,558070,138Jan 24 05:06 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJan 21Option Exercise0.005,354061,665Jan 24 05:05 PM
Walbert Timothy PChairman, President and CEOJan 21Option Exercise0.0020,3360694,558Jan 24 05:04 PM
Walbert Timothy PChairman, President and CEOJan 14Option Exercise22.1425,000553,500699,222Jan 14 06:44 PM
Walbert Timothy PChairman, President and CEOJan 14Sale90.0225,0002,250,412674,222Jan 14 06:44 PM
Pasternak AndyEVP and Chief Business OfficerJan 06Sale99.577,987795,29640,972Jan 06 09:02 PM
Walbert Timothy PChairman, President and CEODec 31Option Exercise22.1425,000553,500529,482Jan 04 05:00 PM
Walbert Timothy PChairman, President and CEODec 31Sale108.0775,0008,105,487454,482Jan 04 05:00 PM
Hoelscher Paul W.EVP, CFODec 28Option Exercise15.968,575136,8579,624Dec 30 09:00 PM
Hoelscher Paul W.EVP, CFODec 28Sale110.008,575943,2501,049Dec 30 09:00 PM
Pasternak AndyEVP and Chief Business OfficerDec 07Sale100.001,525152,50021,830Dec 08 06:35 PM
McHugh Miles WSr VP & Princ. Acctg OfficerDec 01Option Exercise22.1479,4841,759,776116,005Dec 03 05:20 PM
McHugh Miles WSr VP & Princ. Acctg OfficerDec 01Sale106.6279,4848,474,58436,521Dec 03 05:20 PM
Walbert Timothy PChairman, President and CEONov 30Sale102.4050,0005,119,881504,482Dec 01 05:58 PM
MOZE BARRYEVP, Chief Admin. OfficerNov 04Option Exercise14.7775,7431,118,556151,424Nov 05 05:00 PM
Pasternak AndyEVP and Chief Business OfficerNov 04Option Exercise29.5223,251686,37053,523Nov 05 05:00 PM
MOZE BARRYEVP, Chief Admin. OfficerNov 04Sale112.2875,7438,504,20875,681Nov 05 05:00 PM
Pasternak AndyEVP and Chief Business OfficerNov 04Sale113.0430,1683,410,18123,355Nov 05 05:00 PM
Walbert Timothy PChairman, President and CEONov 01Sale118.4925,0002,962,327554,482Nov 03 04:30 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerOct 27Option Exercise7.6110,72981,64819,844Oct 29 04:55 PM